Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Originally engineered at Washington State University by the Harding lab and later licensed to M3 Biotechnology, Dihexa retains the angiotensin IV pharmacophore for AT4 receptor binding while incorporating N-hexanoyl and aminohexanoic acid modifications that confer metabolic stability and lipophilic BBB penetration
This is thanks to growing clinical evidence
These overlapping effects likely produce additive rather than synergistic benefits in specific pathway components
Quality of life of patients with high-grade spondylolisthesis: minimum 2-year follow-up after surgical and nonsurgical treatments
US$ 21.71
US$ 25.20
US$ 24.58
US$ 24.11
US$ 23.56
